Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial

Wiley - Tập 54 Số 3 - Trang 702-710 - 2006
Sofía Ramiro1, Désirée van der Heijde2, E. William St. Clair3, Paul Emery4, Joan M. Bathon5, Edward Keystone6, Ravinder N. Maini7, Joachim R. Kalden8, Michael Schiff9, Daniel Baker10, Chenglong Han10, John Han10, Mohan Bala10
1Medical University of Vienna, and Lainz Hospital, Vienna, Austria
2University of Maastricht, Maastricht, the Netherlands
3Duke University, Durham, North Carolina
4University of Leeds, Leeds, UK
5Johns Hopkins University, Baltimore, Maryland
6University of Toronto, Toronto, Ontario, Canada
7Kennedy Institute of Rheumatology, London, UK
8University of Erlangen, Erlangen, Germany
9Denver Arthritis Clinic, Denver, Colorado
10Centocor, Malvern, Pennsylvania

Tóm tắt

AbstractObjectiveTo identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated with methotrexate (MTX) versus those treated with infliximab plus MTX.MethodsPatients who had not previously been treated with MTX with active RA were randomly assigned to receive escalating doses of MTX up to 20 mg/week plus placebo or infliximab at weeks 0, 2, and 6, and every 8 weeks thereafter through week 46. Radiographic joint damage was assessed using the modified Sharp/van der Heijde score (SHS). The relationship between disease activity measures at baseline and week 14, as well as those averaged over time, were examined in relation to the change in SHS from baseline through week 54.ResultsC‐reactive protein (CRP) levels, erythrocyte sedimentation rate (ESR), and swollen joint count were associated with greater joint damage progression in the MTX‐only group, while none of these parameters was associated with progression in the infliximab plus MTX group. Mean changes in SHS among patients in the highest CRP (≥3 mg/dl) and ESR (≥52 mm/hour) tertiles in the MTX‐only group were 5.62 and 5.89, respectively, compared with 0.73 and 1.12 in the infliximab plus MTX group (P < 0.001). Patients with greater joint damage at baseline (SHS ≥10.5) showed less progression with infliximab plus MTX compared with MTX alone (−0.39 versus 4.11; P < 0.001). Patients receiving MTX alone who had persistently active disease at week 14 showed greater radiographic progression of joint damage than those taking MTX plus infliximab.ConclusionHigh CRP level, high ESR, or persistent disease activity was associated with greater radiographic progression in the group taking MTX alone, while little radiographic progression was seen in patients receiving both MTX and infliximab, regardless of the abnormal levels of these traditional predictors.

Từ khóa


Tài liệu tham khảo

10.1136/ard.43.1.8

10.1038/nature01661

10.1146/annurev.immunol.14.1.397

10.1002/1529-0131(199909)42:9<1854::AID-ANR9>3.0.CO;2-F

10.1016/S0140-6736(87)91672-2

10.1002/1529-0131(200109)44:9<2009::AID-ART349>3.0.CO;2-L

Van Leeuwen MA, 1994, Interrelationship of outcome measures and process variables in early rheumatoid arthritis: a comparison of radiologic damage, physical disability, joint counts, and acute phase reactants, J Rheumatol, 21, 425

Graudal N, 2000, Inflammatory patterns in rheumatoid arthritis estimated by the number of swollen and tender joints, the erythrocyte sedimentation rate, and hemoglobin: long term course and association to radiographic progression, J Rheumatol, 27, 47

10.1093/rheumatology/37.11.1220

10.1002/1529-0131(200108)44:8<1736::AID-ART308>3.0.CO;2-I

10.1136/ard.60.10.924

Guillemin F, 2003, Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients, J Rheumatol, 30, 2585

10.1002/1529-0131(200007)43:7<1473::AID-ANR9>3.0.CO;2-N

Smolen JS, 2003, A proposed treatment algorithm for rheumatoid arthritis: aggressive therapy, methotrexate, and quantitative measures, Clin Exp Rheumatol, 21, S209

10.1136/ard.62.suppl_2.ii94

10.1038/nrd1109

10.1093/rheumatology/25.1.44

10.1093/rheumatology/37.11.1157

10.1016/S0140-6736(97)01300-7

10.1016/S0140-6736(98)08513-4

10.1093/rheumatology/keh199

10.1016/S0002-9343(01)00872-5

Aletaha D, 2002, Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis: an observational study, J Rheumatol, 29, 1631

10.1056/NEJM200011303432201

10.1002/art.20568

10.1016/S0140-6736(04)15640-7

10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W

10.1136/ard.62.suppl_2.ii2

10.1002/art.1780360601

KoepkeJ BullB van AssendelftO.Reference procedure for the erythrocyte sedimentation rate (ESR) test.National Committee for Clinical Laboratory Standards;1988. Document H2–A2.

Stites DP, 1997, Medical immunology, 211

10.1002/art.1780380107

10.1093/rheumatology/keg072

10.1016/S0140-6736(89)92442-2

Fisher LD, 1993, Biostatistics: a methodology for the health sciences

10.1002/art.1780230202

10.1016/S0140-6736(04)16676-2

10.1093/rheumatology/39.2.122

Kalden JR, 2002, Expanding role of biologic agents in rheumatoid arthritis, J Rheumatol Suppl, 66, 27

10.1002/art.11358

10.1093/rheumatology/33.11.1017

10.1002/art.10817

10.1186/ar1740

10.1002/art.20982

10.1002/art.21405

Thông tin
Thông tin xuất bản

Wiley

Tập 54 Số 3

702-710

Thông tin tác giả